Invesco Ltd. Purchases 519,186 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Invesco Ltd. boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 91.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,084,753 shares of the company’s stock after acquiring an additional 519,186 shares during the quarter. Invesco Ltd.’s holdings in Medpace were worth $360,387,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in MEDP. Proficio Capital Partners LLC lifted its position in shares of Medpace by 34,497.4% in the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock valued at $80,575,000 after buying an additional 241,827 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Medpace in the 4th quarter valued at $78,144,000. Norges Bank acquired a new stake in Medpace during the 4th quarter valued at $69,859,000. GW&K Investment Management LLC boosted its position in Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after purchasing an additional 133,379 shares during the period. Finally, Thrivent Financial for Lutherans increased its holdings in shares of Medpace by 738.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 120,928 shares of the company’s stock valued at $40,176,000 after purchasing an additional 106,498 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Up 9.1 %

NASDAQ MEDP opened at $302.56 on Thursday. The business’s fifty day simple moving average is $325.79 and its 200-day simple moving average is $335.08. The firm has a market cap of $9.15 billion, a PE ratio of 23.96, a P/E/G ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 52 week low of $272.00 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on MEDP shares. Leerink Partners assumed coverage on Medpace in a report on Monday, March 24th. They set a “market perform” rating and a $330.00 price target for the company. Leerink Partnrs raised Medpace to a “hold” rating in a report on Monday, March 24th. Mizuho decreased their price target on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Robert W. Baird lifted their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Medpace currently has an average rating of “Hold” and a consensus target price of $368.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.